EarliPoint Health receives expanded FDA clearance for autism assessment in children up to age 8.

Read Release →

Closing the Gap: Why Autism Diagnosis Before Age Three Matters

On This Page

A difference of a few years may not sound like much, but in autism spectrum disorder, earlier identification can open critical windows for support during key stages of development. When a diagnosis comes at age three, it allows families to begin targeted interventions sooner.

What the Research Actually Shows

The science is clear: earlier identification of autism can meaningfully improve outcomes. A review published in Cureus found that diagnosis between 18 and 24 months creates an important opportunity to begin support during a period of rapid brain development.

This is driven by neuroplasticity. In the first few years of life, the brain is forming connections at an extraordinary pace. Interventions during this time can help shape developing neural pathways to support learning and development.

Research reflects this impact. In one study, children aged 18 to 30 months who received the Early Start Denver Model intervention improved by an average of 17.6 standard score points over two years, compared to 7.0 points in a community intervention group. Another study found that children who began intervention at 18 months made greater gains than those who started at 27 months, showing that even relatively small differences in timing can matter.

At the same time, it is important to recognize that children can make meaningful progress at any age. Early identification expands this opportunity, but it is never too late to support growth and development.

The Gap Between What is Possible and What is Happening

Autism spectrum disorder can be reliably identified as early as 18 months by an experienced clinician. The average age of diagnosis in the United States has remained above four years for more than two decades. Only a minority of children with autism are identified before age three. Subtler presentations in girls and in children without severe language delays are frequently missed. Rural and lower-income families face the steepest barriers.

Why Timing Matters

When autism is identified later, it often means a child has spent important early developmental years without targeted support. During this time, differences in communication, learning, and social engagement may continue to evolve without intervention, making some skills more complex to build over time.

Research consistently shows that earlier diagnosis, particularly before age 3, is associated with greater gains in key areas such as social functioning. For example, children diagnosed before 2.5 years of age have been shown to be significantly more likely to demonstrate meaningful improvements compared to those identified later. Even within what is often considered “early intervention,” studies show that children who begin therapy in the earlier part of that window (e.g., 36–47 months) experience greater reductions in core autism symptoms than those who start later.

Importantly, children can make meaningful progress at any age with the right support. But identifying autism earlier creates an opportunity to begin intervention during a period of rapid development, when it can have the greatest impact.

Why an Accurate Diagnosis is the Foundation, Not the Finish Line

A diagnosis is only as valuable as what follows from it. A recent Wall Street Journal investigation, which raised serious concerns about the autism therapy industry, found that Medicaid spending on Applied Behavior Analysis more than tripled between 2019 and 2023, with federal audits confirming widespread improper payments. Rushing toward therapy without a rigorous diagnosis harms children in both directions: those who need early intervention may not receive the right kind, and those who do not may receive unnecessary treatment at high cost.

The Bottom Line

A diagnosis at three is not a guarantee of any particular outcome. But the evidence points clearly in one direction: the earlier a child with autism is accurately identified, the more the intervention that follows can do. The question is not whether early diagnosis matters; it is why the system has taken this long to treat it as the priority it is.

Cheryl Tierney, MD, MPH

Chief Medical Officer

Developmental pediatrician, public health advocate, and Chief Medical Officer at EarliPoint Health. Cheryl blends scientific curiosity with real-world passion — as a physician, professor, and mom, she’s committed to turning early autism research into better care and support for families.

Cheryl Tierney, MD, MPH

Chief Medical Officer

Cheryl serves as EarliPoint’s Chief Medical Officer, helping advance early autism research into more accessible care and support for families.

See how EarliPoint fits seamlessly into your clinical workflow.

Jamie Pagliaro brings over two decades of leadership in autism and behavioral health to his role as President and CEO of EarliPoint. Most recently, he served as Chief Operating Officer at Rethink, a leading SaaS provider supporting individuals with autism and developmental disabilities. Under his leadership, Rethink’s behavioral health division became the company’s largest business unit, serving thousands of clinicians and driving scalable, tech-enabled care delivery.

Earlier in his career, Jamie was Executive Director of the New York Center for Autism Charter School, the first public charter school in New York State dedicated to children with autism. At EarliPoint, he leads the company’s mission to bring breakthrough science to the front lines of care—empowering providers, families, and health systems with earlier answers and better outcomes.

Jamie Pagliaro

President & Chief Executive Officer

Dr. Ami Klin is a globally recognized leader in autism research and early detection. As Director of the Marcus Autism Center and Division Chief of Autism and Developmental Disabilities at Emory University School of Medicine, he has dedicated his career to understanding how young children engage with the social world—and how subtle disruptions in attention can signal developmental differences. His pioneering work in eye-tracking science led to the development of EarliPoint™ Evaluation, the first FDA-authorized tool to objectively assess autism in children as young as 16 months.
At EarliPoint, Dr. Klin drives clinical strategy and innovation, ensuring that families and clinicians worldwide have access to timely, science-based insights that enable earlier, more personalized intervention. His career reflects a deep commitment to transforming how society supports children with autism—starting with the earliest signs.

Ami Klin, PhD

Chief Clinical Officer & Co‑Founder